Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 11/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.35 |
| ▸ | LPO | P22079 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6743060 | 0.84 | FDPS (0.45) | FDPS | |
| Zoledronic Acid Anhydrous SCHEMBL9850927 | 0.80 | FDPS (0.60) | FDPSMEN1KMT2A | |
| Phosphoric Acid SCHEMBL28269754 | 0.77 | FDPS (0.60) | FDPSMEN1KMT2AHTTTSHR | |
| Phosphoric Acid SCHEMBL4397370 | 0.77 | FDPS (0.60) | FDPSMEN1KMT2AHTTTSHR | |
| SCHEMBL13916698 | 0.75 | FDPS (0.44) | FDPSMEN1KMT2AHTTTSHR | |
| Methyl Phosphonate SCHEMBL2525334 | 0.75 | FDPS (0.58) | FDPSMEN1KMT2AHTTTSHR | |
| SCHEMBL6242617 | 0.74 | FDPS (0.45) | FDPSMEN1KMT2ATSHROPRK1 | |
| SCHEMBL19182738 | 0.74 | FDPS (0.57) | FDPSMEN1KMT2AHTTTSHR | |
| SCHEMBL3979171 | 0.74 | FDPS (0.43) | FDPSMEN1KMT2AHTTTSHR | |
| SCHEMBL12158386 | 0.72 | FDPS (0.44) | FDPSMEN1KMT2ATSHROPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0854724-B1 | METHOD OF TREATING THE NAVICULAR DISEASE IN HORSES | NOVARTIS AG (CH) | 2005-03-16 | — | — | EP | claimed |
| US-6255288-B1 | THERAPY FOR BONE DISORDERS | NOVARTIS CORPORATION | 2001-07-03 | — | — | US | claimed |
| US-6057306-A | ADMINISTERING BISPHOSPHONATES TO TREAT BONE DISEASE | NOVARTIS CORPORATION (US) | 2000-05-02 | — | — | US | claimed |
| EP-0854724-A1 | METHOD OF TREATING THE NAVICULAR DISEASE IN HORSES | Novartis AG (CH) | 1998-07-29 | — | — | EP | claimed |
| WO-1997012619-A1 | METHOD OF TREATING THE NAVICULAR DISEASE IN HORSES | NOVARTIS AG (CH) | 1997-04-10 | — | — | WO | claimed |
| EP-0600834-A1 | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | claimed |
| EP-0550385-A1 | Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers | CIBA-GEIGY AG (CH) | 1993-07-07 | — | — | EP | claimed |
| US-5133972-A | TOPICALLY ADMINISTRABLE PHARMACEUTICAL PREPARATIONS | CIBA-GEIGY CORPORATION (US) | 1992-07-28 | — | — | US | claimed |
| EP-0275821-B1 | SUBSTITUTED ALKANEDIPHOSPHONIC ACIDS | CIBA-GEIGY AG (CH) | 1992-02-26 | — | — | EP | claimed |
| EP-0407344-A2 | Pharmaceutical preparation for topical application | CIBA-GEIGY AG (CH) | 1991-01-09 | — | — | EP | claimed |
| EP-0275821-A1 | Substituted alkanediphosphonic acids | CIBA-GEIGY AG (CH) | 1988-07-27 | — | — | EP | claimed |
| US-20130138221-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IMPLANT OSSEOINTEGRATION | NOVARTIS AG (CH) | 2013-05-30 | — | — | US | disclosed |
| US-20120027818-A1 | BISPHOSPHONATE PRODUCT IN A CYCLOOLEFINIC POLYMER CONTAINER | GLAUSCH ALEXANDRA (DE) | 2012-02-02 | — | — | US | disclosed |
| US-8052987-B2 | Intermittently administering a bisphosphonate to patient, wherein period between administrations of bisphosphonate is at least 6 months; treatment of osteoporosis | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2011-11-08 | — | — | US | disclosed |
| US-7932241-B2 | Filling plastic container with bisphosphonate solution; heat sterilization | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-5133972-A | TOPICALLY ADMINISTRABLE PHARMACEUTICAL PREPARATIONS | CIBA-GEIGY CORPORATION (US) | 1992-07-28 | — | — | US | disclosed |
| EP-0275821-B1 | SUBSTITUTED ALKANEDIPHOSPHONIC ACIDS | CIBA-GEIGY AG (CH) | 1992-02-26 | — | — | EP | disclosed |
| EP-0407344-A2 | Pharmaceutical preparation for topical application | CIBA-GEIGY AG (CH) | 1991-01-09 | — | — | EP | disclosed |
| US-4939130-A | Substituted alkanediphosphonic acids and pharmaceutical use | CIBA-GEIGY CORPORATION (US) | 1990-07-03 | — | — | US | disclosed |
| EP-0275821-A1 | Substituted alkanediphosphonic acids | CIBA-GEIGY AG (CH) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027818-A1 | BISPHOSPHONATE PRODUCT IN A CYCLOOLEFINIC POLYMER CONTAINER | PGD, RICTOR, PAICS | FDPS 90/4885MEN1 249/4885KMT2A 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.